摘要
Abstract
Objective To explore the effect of sodium phosphocreatine combined with levocarnitine on patients with viral myocarditis(VMC).Methods A prospective study was conducted on 96 patients with VMC.They were randomly divided into a control group and an observation group by using the random number table method,each with 48 cases.Among them,the control group was given levocarnitine,while the observation group was given sodium phosphocreatine combined with levocarnitine.Both groups were continuously treated for two weeks.The clinical efficacy and adverse reaction rates between the two groups were compared,as well as the levels of myocardial enzyme spectrum markers[creatine phosphokinase(CK)and creatine kinase MB(CK-MB)],relevant serum factors[tumor necrosis factor(TNF)-α,C-reactive protein(CRP)and interleukin(IL)-6],and oxidative stress indicators[malondialdehyde(MDA),advanced oxidation protein products(AOPP)and superoxide dismutase(SOD)]before and after treatment.Results The difference of the total clinical effective rate was statistically significant between the two groups(P<0.05).The improvement of myocardial enzyme spectrum,related serum factors,and oxidative stress indicators in the observation group after treatment was all superior to that in the control group(all P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of sodium phosphocreatine and levocarnitine has a significant therapeutic effect on VMC,which could regulate myocardial enzyme spectrum,improve oxidative stress response,and inhibit inflammatory response in vivo with relatively high safety.关键词
磷酸肌酸钠/左卡尼汀/病毒性心肌炎/心肌酶谱/氧化应激Key words
sodium phosphocreatine/levocarnitine/viral myocarditis/myocardial enzyme spectrum/oxidative stress分类
医药卫生
